Clinical identification and management of chronic HBV carriers / 临床肝胆病杂志

ABSTRACT

As reported by the world health organization, about 650 thousand people die of liver failure, liver cirrhosis, and hepatocellular carcinoma caused by hepatitis B virus (HBV) infection every year. Although to a certain extent, the application of interferon and nucleos(t)ide analogues reduces the adverse outcome of chronic hepatitis B (CHB), so far no effective therapeutic method can eliminate HBV. HBV carriers have a significantly lower incidence rate of adverse outcome than active CHB patients, but they still have the risk of progression to liver cirrhosis and liver cancer. This article discusses the clinical identification and management of HBV carriers, so as to further clarify the features of chronic HBV carriers and related treatment measures in clinical practice.